Advertisement
Singapore markets close in 2 hours 37 minutes
  • Straits Times Index

    3,322.54
    -3.74 (-0.11%)
     
  • Nikkei

    39,667.07
    +493.92 (+1.26%)
     
  • Hang Seng

    18,110.84
    +37.94 (+0.21%)
     
  • FTSE 100

    8,247.79
    -33.76 (-0.41%)
     
  • Bitcoin USD

    61,622.86
    +595.68 (+0.98%)
     
  • CMC Crypto 200

    1,277.47
    -6.32 (-0.49%)
     
  • S&P 500

    5,469.30
    +21.43 (+0.39%)
     
  • Dow

    39,112.16
    -299.05 (-0.76%)
     
  • Nasdaq

    17,717.65
    +220.84 (+1.26%)
     
  • Gold

    2,322.90
    -7.90 (-0.34%)
     
  • Crude Oil

    81.29
    +0.46 (+0.57%)
     
  • 10-Yr Bond

    4.2380
    -0.0100 (-0.24%)
     
  • FTSE Bursa Malaysia

    1,589.82
    +4.44 (+0.28%)
     
  • Jakarta Composite Index

    6,925.67
    +42.96 (+0.62%)
     
  • PSE Index

    6,299.21
    +0.16 (+0.00%)
     

Agenus Announces Virtual Annual Shareholders Meeting

LEXINGTON, Mass., June 04, 2024--(BUSINESS WIRE)--Agenus Inc. ("Agenus") (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 11, 2024, and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET.

To participate in the Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com/AGEN2024 and enter the 16-digit control number found in their proxy materials. Guests may also access the Annual Shareholders Meeting, but in listen-only mode. No control number is required for guests.

Webcast Information:

Date: Tuesday, June 11, 2024

ADVERTISEMENT

Time: 10:30 a.m. ET

A live webcast and replay will be accessible on the Company’s website at https://investor.agenusbio.com/events-and-presentations and at www.virtualshareholdermeeting.com/AGEN2024.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240604262147/en/

Contacts

Investor
917-362-1370
investor@agenusbio.com

Media
612-839-6748
communications@agenusbio.com